- Home
- EVF vs IMUX Comparison
EVF vs IMUX Comparison
Compare EVF & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVF
- IMUX
- Stock Information
- Founded
- EVF 1998
- IMUX 2016
- Country
- EVF United States
- IMUX United States
- Employees
- EVF N/A
- IMUX N/A
- Industry
- EVF Investment Managers
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- EVF Finance
- IMUX Health Care
- Exchange
- EVF Nasdaq
- IMUX Nasdaq
- Market Cap
- EVF 101.5M
- IMUX 94.9M
- IPO Year
- EVF N/A
- IMUX N/A
- Fundamental
- Price
- EVF $5.63
- IMUX $1.02
- Analyst Decision
- EVF
- IMUX Strong Buy
- Analyst Count
- EVF 0
- IMUX 6
- Target Price
- EVF N/A
- IMUX $13.20
- AVG Volume (30 Days)
- EVF 93.3K
- IMUX 1.3M
- Earning Date
- EVF 01-01-0001
- IMUX 05-20-2025
- Dividend Yield
- EVF 10.68%
- IMUX N/A
- EPS Growth
- EVF N/A
- IMUX N/A
- EPS
- EVF 0.94
- IMUX N/A
- Revenue
- EVF N/A
- IMUX N/A
- Revenue This Year
- EVF N/A
- IMUX N/A
- Revenue Next Year
- EVF N/A
- IMUX N/A
- P/E Ratio
- EVF $6.74
- IMUX N/A
- Revenue Growth
- EVF N/A
- IMUX N/A
- 52 Week Low
- EVF $5.20
- IMUX $0.83
- 52 Week High
- EVF $6.84
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- EVF 49.69
- IMUX 47.20
- Support Level
- EVF $5.55
- IMUX $0.96
- Resistance Level
- EVF $5.70
- IMUX $1.22
- Average True Range (ATR)
- EVF 0.07
- IMUX 0.12
- MACD
- EVF 0.03
- IMUX -0.00
- Stochastic Oscillator
- EVF 68.97
- IMUX 19.44
About EVF Eaton Vance Senior Income Trust
Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.